rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CRBP
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Corbus Pharmaceuticals Starts Phase 3 Cancer Study, Weighs Next Steps for Obesity Drug
      17h agoYahoo FinanceCRBP
      Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
      Nov 16Yahoo FinanceCRBP
      Mizuho cuts Corbus Pharmaceuticals stock price target on model tweaks
      Nov 12Investing.comCRBP
      Oppenheimer cuts Corbus Pharmaceuticals stock price target to $40
      Nov 11Investing.comCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Nov 10MarketWatchCRBP
      Corbus Pharmaceuticals: Q3 Earnings Snapshot
      Nov 10Yahoo FinanceCRBP
      Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
      Nov 10Yahoo FinanceCRBP
      Corbus Pharmaceuticals at Guggenheim healthcare conference: two-pronged push
      Nov 9Investing.comCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
      Nov 5MarketWatchCRBP
      Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
      Nov 5Yahoo FinanceCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
      Nov 2MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Oct 27MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day
      Oct 26MarketWatchCRBP
      Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
      Oct 22Yahoo FinanceCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day
      Oct 21MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
      Oct 19MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Oct 16MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
      Oct 15MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
      Oct 14MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
      Oct 13MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
      Oct 12MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Oct 9MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
      Oct 8MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors
      Oct 7MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day
      Oct 6MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
      Oct 5MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day
      Oct 2MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
      Oct 1MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Sep 30MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
      Sep 29MarketWatchCRBP
      Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer

      Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14,000 patients eligible for treatment annually NORWOOD, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that the first patient has been dosed in i

      Sep 29Yahoo FinanceCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors
      Sep 28MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
      Sep 25MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
      Sep 24MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day
      Sep 23MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Sep 22MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Sep 21MarketWatchCRBP
      Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day
      Sep 18MarketWatchCRBP
      Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy - Slideshow (NASDAQ:CRBP) 2026-09-17

      2026-09-17. The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc.

      Sep 17Seeking AlphaCRBP
      Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

      Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.

      Sep 17Yahoo FinanceCRBP
      Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
      Sep 15MarketWatchCRBP
      H.C. Wainwright reiterates Corbus stock rating on phase 1b data
      Sep 15Investing.comCRBP
      Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study

      Corbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average b

      Sep 15Yahoo FinanceCRBP
      Analysts’ Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

      Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailCRBP
      Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
      Sep 14BenzingaCRBP
      Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data
      Sep 14Yahoo FinanceCRBP
      Why is Corbus Pharmaceuticals stock surging today?
      Sep 14Investing.comCRBP
      Corbus reports phase 1b obesity drug trial results
      Sep 14Investing.comCRBP
      Corbus Pharmaceuticals stock rises on obesity drug trial data
      Sep 14Investing.comCRBP
      Trial breakthrough for weight-loss drug with fewer side effects
      Sep 14Financial TimesCRBPLLY

      This is the newest page. Registered accounts read further back.